Adrian Cheng's K11 mall joins Chanel and Burberry in issuing a sustainability-linked bond, which commits the company to a renewable-energy goal.

Hong Kong healthcare fund manager and other shareholders this week announced exit from Kymab in $1.1 billion deal with French drugmaker Sanofi.

The secondaries may have struggled to find their feet after the global financial crisis, but have been a quiet achiever over the past few years. In Asia, they are now seen as set to blossom.

After the rapid strides it has made as a destination for biotech listings in less than three years, Hong Kong now faces bigger challenges in overtaking New York.

Companies floating shares in city expected to raise between $54.2 billion and $59.3 billion this year, with biotech listings continuing to be active.

After the Covid-19 shock of 2020, what should one expect in 2021? This is where some influential money managers in the region see opportunities and challenges.

While Uzbekistan and Kazakhstan remain capital markets rivals, the latter appears to be pulling ahead.

It was once off-limits, but now MPF fund managers can put more of the pension pot into mainland China’s thriving and tech-heavy bourses in Shanghai and Shenzhen.

We set out our rationale for why we chose the winners of our house awards.

We set out the rationale for the choices we made for our issuer and deal awards.